Founded at the Abramson Cancer Center at the University of Pennsylvania

The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States

The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States

Journal of Medical Economics | 2020

Rachael Louise Slater; Yizhen Lai; Yichen Zhong; Haojie Li; Yang Meng; Blanca Homet Moreno; James Luke Godwin; Tara Frenkl; Guru P. Sonpavde; Ronac Mamtani